West Pharmaceutical Services, Inc.
WST
$213.06
-$1.68-0.78%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 698.00M | 748.80M | 746.90M | 702.10M | 695.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 698.00M | 748.80M | 746.90M | 702.10M | 695.40M |
| Cost of Revenue | 466.10M | 475.20M | 482.20M | 472.10M | 465.20M |
| Gross Profit | 231.90M | 273.60M | 264.70M | 230.00M | 230.20M |
| SG&A Expenses | 86.60M | 83.30M | 81.90M | 83.00M | 86.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 300.00K | 0.00 | 600.00K | -- | 300.00K |
| Total Operating Expenses | 569.30M | 577.00M | 580.20M | 572.60M | 569.80M |
| Operating Income | 128.70M | 171.80M | 166.70M | 129.50M | 125.60M |
| Income Before Tax | 113.90M | 166.90M | 168.40M | 133.20M | 131.70M |
| Income Tax Expenses | 24.10M | 36.80M | 32.40M | 21.90M | 16.40M |
| Earnings from Continuing Operations | 89.80M | 130.10M | 136.00M | 111.30M | 115.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.80M | 130.10M | 136.00M | 111.30M | 115.30M |
| EBIT | 128.70M | 171.80M | 166.70M | 129.50M | 125.60M |
| EBITDA | 168.70M | 212.50M | 206.90M | 168.40M | 161.20M |
| EPS Basic | 1.24 | 1.79 | 1.87 | 1.52 | 1.57 |
| Normalized Basic EPS | 1.16 | 1.52 | 1.46 | 1.15 | 1.13 |
| EPS Diluted | 1.23 | 1.78 | 1.85 | 1.51 | 1.55 |
| Normalized Diluted EPS | 1.15 | 1.51 | 1.45 | 1.14 | 1.12 |
| Average Basic Shares Outstanding | 72.50M | 72.70M | 72.80M | 73.00M | 73.50M |
| Average Diluted Shares Outstanding | 73.00M | 73.30M | 73.40M | 73.70M | 74.30M |
| Dividend Per Share | 0.21 | 0.21 | 0.20 | 0.20 | 0.20 |
| Payout Ratio | 16.93% | 11.76% | 10.66% | 13.12% | 12.75% |